Can a patient with mild to moderate impaired renal function (GFR of 52) take Macrobid (nitrofurantoin) for a urinary tract infection (UTI)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: July 30, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Nitrofurantoin Use in Patients with GFR of 52 mL/min

Yes, a patient with a GFR of 52 mL/min can safely take Macrobid (nitrofurantoin) for a urinary tract infection. While traditional contraindications suggested avoiding nitrofurantoin in patients with GFR <60 mL/min, current evidence supports its use in patients with GFR ≥30 mL/min.

Evidence-Based Rationale

Current Guidelines and Recommendations

The American Urological Association and American College of Physicians recommend nitrofurantoin as a first-line treatment for uncomplicated UTIs 1. The traditional contraindication of nitrofurantoin in patients with GFR <60 mL/min has been challenged by more recent evidence.

The 2014 KDOQI Clinical Practice Guidelines do not specifically list nitrofurantoin as contraindicated in patients with GFR >30 mL/min 2. In fact, the comprehensive table of medication precautions for CKD patients does not include specific restrictions for nitrofurantoin at the GFR level of 52 mL/min.

Efficacy and Safety Considerations

Research has demonstrated that:

  • The contraindication of nitrofurantoin in patients with GFR <60 mL/min lacks strong evidence and was based on limited pharmacokinetic studies from the 1960s that had significant methodological limitations 3
  • Studies examining clinical outcomes (rather than just urinary drug concentrations) have not shown significant differences in treatment failure rates that would justify avoiding nitrofurantoin in patients with mild to moderate renal impairment 4

Antimicrobial Stewardship Benefits

Using nitrofurantoin in appropriate patients with reduced GFR offers several advantages:

  • Preserves fluoroquinolones for more serious infections
  • Provides an alternative to trimethoprim-sulfamethoxazole in areas with high resistance
  • Maintains good activity against common UTI pathogens including E. coli 5
  • Has minimal impact on gut flora compared to other antibiotics 1

Practical Recommendations

For a patient with GFR of 52 mL/min:

  1. Nitrofurantoin (Macrobid) 100 mg twice daily for 5-7 days is appropriate
  2. Monitor for clinical response within 48-72 hours
  3. Be alert for rare but serious adverse effects such as pulmonary reactions, though these are primarily associated with long-term use rather than short courses 5
  4. No dosage adjustment is necessary at this level of renal function

Important Caveats

  • If the patient has recurrent UTIs requiring frequent antibiotic courses, consider urologic evaluation
  • Avoid nitrofurantoin for suspected pyelonephritis or systemic infection
  • If symptoms do not improve within 72 hours, obtain urine culture with susceptibility testing and consider alternative antibiotics
  • The contraindication for nitrofurantoin in severe renal impairment (GFR <30 mL/min) remains valid due to concerns about efficacy and potential toxicity 1

In summary, for a patient with a GFR of 52 mL/min, nitrofurantoin is a safe and effective option for treating an uncomplicated UTI, aligning with current antimicrobial stewardship principles.

References

Guideline

Treatment of Urinary Tract Infections

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Kidney function and the use of nitrofurantoin to treat urinary tract infections in older women.

CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 2015

Research

[Nitrofurantoin--clinical relevance in uncomplicated urinary tract infections].

Medizinische Monatsschrift fur Pharmazeuten, 2014

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.